



Financial Statements

As of and For the Year Ended December 31, 2016

with Independent Auditor's Report

ALASKA VACCINE ASSESSMENT PROGRAM  
Table of Contents  
As of and For the Year Ended December 31, 2016

Independent Auditor’s Report .....	1-2
Financial Statements	
Statement of Net Assets .....	3
Statement of Activities.....	4
Statement of Cash Flows .....	5
Notes to the Financial Statements.....	6-8
Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i> .....	9-10



## INDEPENDENT AUDITOR'S REPORT

To the Council Members  
Alaska Vaccine Assessment Program  
Anchorage, Alaska

### **Report on the Financial Statements**

I have audited the accompanying financial statements of the Alaska Vaccine Assessment Program, which comprise the statement of net assets-regulatory basis as of December 31, 2016, and the related statements of activities-regulatory basis and cash flows-regulatory basis for the year then ended, and the related notes to the financial statements.

#### *Management's Responsibility for the Financial Statements*

Management is responsible for the preparation and fair presentation of these financial statements in accordance with the financial reporting provisions under the requirements of the Alaska Vaccine Assessment Program. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

#### *Auditor's Responsibility*

My responsibility is to express an opinion on these financial statements based on my audit. I conducted my audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States of America. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of providing an opinion on the effectiveness of the entity's internal control. Accordingly, I express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

*Opinion*

In my opinion, the financial statements referred to above present fairly, in all material respects, the net assets of the Alaska Vaccine Assessment Program as of December 31, 2016, and the changes in its net assets and its cash flows for the year then ended, in accordance with the financial reporting provisions under the requirements of the Alaska Vaccine Assessment Program.

*Emphasis of Matter – Basis of Accounting*

I draw attention to Note 2 of the financial statements, which describes the basis of accounting. The financial statements are prepared in accordance with the financial reporting provisions under the requirements of the Alaska Vaccine Assessment Program, which is a basis of accounting other than accounting principles generally accepted in the United States of America. My opinion is not modified with respect to that matter.

**Report on Other Legal and Regulatory Requirements – *Government Auditing Standards***

In accordance with *Government Auditing Standards*, I have also issued my report dated August 31, 2017 on my consideration of Alaska Vaccine Assessment Program's internal control over financial reporting and my tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of my testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of Alaska Vaccine Assessment Program's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Alaska Vaccine Assessment Program's internal control over financial reporting and compliance.

August 31, 2017

Handwritten signature of Laura Lindal CPA in blue ink.

Kirkland, Washington

ALASKA VACCINE ASSESSMENT PROGRAM  
Statement of Net Assets - Regulatory Basis  
December 31, 2016

ASSETS

Cash	
Held by the State of Alaska	\$ 5,328,788
Held by KidsVax® LLC	43,718
	<u>5,372,506</u>
Assessments receivable	
Payers	7,702
Providers	259,938
	<u>267,640</u>
Total assets	5,640,146

LIABILITIES

Accounts payable	
Vaccines	3,906,291
Equipment	72,726
KidsVax®	25,000
Department of Health administrative fee	59,687
Others	6,100
Refunds due to payers	337,012
Refunds due to providers	13,572
Assessments collected in excess of vaccine funding and administrative activities	1,219,758
	<u>5,640,146</u>
Total liabilities	5,640,146

NET ASSETS

Net assets	\$ <u><u>          -</u></u>
------------	------------------------------

The accompanying notes should be read with these financial statements.

ALASKA VACCINE ASSESSMENT PROGRAM  
Statement of Activities - Regulatory Basis  
For the Year Ended December 31, 2016

Assessments	
Payer assessments - children	\$ 6,674,737
Payer assessments - adults	2,127,718
Provider assessments	<u>405,376</u>
	9,207,831
Interest income	<u>453</u>
Total revenue	<u>9,208,284</u>
Program expense	
Vaccines	8,580,386
Equipment	100,361
Department of Health administrative fee	138,102
Servicing agent	381,666
Credits to payers and providers	<u>6,655</u>
	9,207,170
Administrative costs	<u>14,974</u>
Total expenses	<u>9,222,144</u>
Change in net assessments collected	(13,860)
Assessments collected in excess of vaccine funding and administrative activities, beginning of year	<u>1,233,618</u>
Assessments collected in excess of vaccine funding and administrative activities, end of year	<u>\$ 1,219,758</u>

The accompanying notes should be read with these financial statements.

ALASKA VACCINE ASSESSMENT PROGRAM  
Statement of Cash Flows - Regulatory Basis  
For the Year Ended December 31, 2016

Cash Flows from Operating Activities:	
Change in net assessments collected	\$ (13,860)
Adjustments to reconcile change in net assets to net cash from operating activities:	
Changes in assets and liabilities	
Assessments receivable	(100,022)
Accounts payable - vaccines	(1,076,936)
Accounts payable - nonvaccine purchases	101,718
Refunds due	80,700
Net change in cash	(1,008,400)
Cash, beginning of year	6,380,906
Cash, ending of year	\$ 5,372,506

The accompanying notes should be read with these financial statements.

ALASKA VACCINE ASSESSMENT PROGRAM  
Notes to the Financial Statements  
For the Year Ended December 31, 2016

NOTE 1 – NATURE AND PURPOSE OF THE PROGRAM

The Alaska Vaccine Assessment Program (AVAP) is a program enacted by the State of Alaska legislature in June 2014 and authorized under Alaska Statute 18.09.200 to establish a vaccine assessment account that will enable the Alaska Department of Health and Social Services (DHSS) to purchase all pediatric and most adult vaccines at costs below those of private purchase alternatives.

AVAP facilitates the universal purchase of vaccines in Alaska. It provides funding for all vaccines federally recommended for insured children and for certain adult vaccines selected by the DHSS. By collecting payments from health plans, insurers, and other responsible entities and remitting those funds to the State of Alaska, the Program ensures

- Alaskans gain improved access to vaccines;
- Health care providers receive state-supplied vaccines at no charge; and
- Payers benefit from cost savings through the State’s bulk vaccine purchase and distribution.

DHSS contracted with KidsVax, LLC based in New Hampshire as the servicing agent for administrative support services, including collection of payments from health plans, insurance companies, and other payers and providers.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying financial statements are prepared from the activities provided for under the Alaska Vaccine Assessment Program, and represent a basis of accounting other than accounting principles generally accepted in the United States of America. The financial statements include the assessments billed to participating payers and providers, as determined by the provisions of the Program, and the expenses that are allowed to be paid from the Program, including vaccines and the costs for administering the program. Vaccines are considered to be an expense of the program when ordered and an inventory balance is not recognized. Equipment purchased for the Program is considered to be an expense of the program and is not capitalized.

In the initial year of the Program, the State of Alaska legislature provided start-up funding of \$250,000 which was to be used for initial equipment purchases and other authorized costs. As of December 31, 2016, \$130,922 had been used for equipment purchases. The remaining funds are included in cash and net assets.

Cash and cash equivalents

Cash represents funds held by the State of Alaska and KidsVax for the benefit of the Alaska Vaccine Assessment Program.



ALASKA VACCINE ASSESSMENT PROGRAM  
Notes to the Financial Statements  
For the Year Ended December 31, 2016

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued

Assessments receivable

Assessments receivable are stated at the amounts management expects to collect from outstanding balances. Management provides for doubtful receivables through an allowance based on its consideration of the current status of individual receivables. Because management considers all of the assessments receivable to be collectible, there was no allowance for doubtful accounts at December 31, 2016.

Assessments collected in excess of vaccine funding and administrative activities

AVAP has collected assessments in excess of amounts required to fund Childhood and Adult vaccines and associated administrative costs. Net assessments collected accumulate and will be used for timely funding of (i) future vaccine funding obligations of the program and (ii) reasonable and necessary operating costs of AVAP.

Revenue recognition

Assessments are recognized when billed to participating payers and providers based on the number of covered lives. Assessments are billed to payers on a quarterly basis and to providers on an annual basis. Assessment rates per covered life are recommended by the State Vaccine Assessment Council and approved by the Commissioner of the State of Alaska Department of Health and Social Services on an annual basis.

Expenses

The terms of the Program allow for DHSS to charge an administrative fee of one and one-half percent (1.5%) of total revenue less credits approved by the Council. This fee is for direct and indirect costs incurred by DHSS in its administration of the Program. Amounts outstanding to DHSS at December 31, 2016 related to its administrative fee totaled \$59,687.

The servicing agent earns its fee on a monthly basis in accordance with services provided to the Program. Amounts outstanding to KidsVax, LLC at December 31, 2016 totaled \$25,000.

Use of estimates in preparation of financial statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect reported amounts and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Subsequent events

Subsequent events have been evaluated through August 31, 2017, which approximates the date the financial statements were available to be issued.

ALASKA VACCINE ASSESSMENT PROGRAM  
Notes to the Financial Statements  
For the Year Ended December 31, 2016

NOTE 3 – CONCENTRATIONS OF RISK

For the year ended December 31, 2016, two payers represented a total of 45% of the assessment revenue.



INDEPENDENT AUDITOR'S REPORT  
ON INTERNAL CONTROL OVER FINANCIAL REPORTING  
AND ON COMPLIANCE AND OTHER MATTERS  
BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED  
IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

To the Council Members  
Alaska Vaccine Assessment Program  
Anchorage, Alaska

I have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of Alaska Vaccine Assessment Program which comprise the statement of net assets-regulatory basis as of December 31, 2016, and the related statements of activities-regulatory basis and cash flows-regulatory basis for the year then ended, and the related notes to the financial statements, and have issued my report thereon dated August 31, 2017.

**Internal Control over Financial Reporting**

In planning and performing my audit, I considered Alaska Vaccine Assessment Program's internal control over financial reporting as a basis for designing my auditing procedures for the purpose of expressing my opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Alaska Vaccine Assessment Program's internal control over financial reporting. Accordingly, I do not express an opinion on the effectiveness of Alaska Vaccine Assessment Program's internal control over financial reporting.

*A deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect and correct misstatements on a timely basis. *A material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. *A significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

My consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during my audit I did not identify any deficiencies in internal control that I consider to be a material weakness. However, material weaknesses may exist that have not been identified.

Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Page 2

**Compliance and Other Matters**

As part of obtaining reasonable assurance about whether Alaska Vaccine Assessment Program's financial statements are free of material misstatement, I performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of my audit, and accordingly, I do not express such an opinion. The results of my tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

**Purpose of this Report**

The purpose of this report is solely to describe the scope of my testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

August 31, 2017

Handwritten signature of Laura Lindal CPA in blue ink.

Kirkland, Washington